We determined a cryo-electron microscopy reconstruction of the gH/gL-gp42-AMMO1 complex and demonstrated that AMMO1 bound to a discontinuous epitope formed by both gH and gL at the Domain-I/Domain-II interface. Integrating structural, biochemical, and infectivity data, we propose that AMMO1 inhibits fusion of the viral and cellular membranes. This work identifies a crucial epitope that may aid in the design of next-generation subunit vaccines against this major public health burden.
In Brief
Epstein-Barr virus is a cancer-associated pathogen for which there is no vaccine. Snijder et al. isolate a monoclonal antibody that neutralizes infection of the major cell types infected by EBV. Structural analysis of the antibody-gH/gL glycoprotein complex reveals a key site of EBV vulnerability that may pave the way for a next-generation EBV vaccine.
INTRODUCTION
Epstein-Barr virus (EBV) infects the majority of adults worldwide. Although most primary infections are asymptomatic, EBV is a causative agent of infectious mononucleosis in children and young adults and is associated with numerous hematopoietic and epithelial cell cancers (Cohen et al., 2011; Young and Rickinson, 2004) . EBV also causes lymphoproliferative disorders in immunocompromised patients such as those with HIV/AIDS or in patients undergoing immune suppression for organ transplantation (Taylor et al., 2015) . Thus, a vaccine that prevents EBV infection would be of major public health benefit (Cohen et al., 2011) . EBV targets B cells and epithelial cells during primary infection. Host cell entry is a complex process mediated by several viral glycoproteins that define tropism and mediate membrane fusion. Three virally encoded surface glycoproteins, gH, gL, and gB, share a conserved function among herpesviruses and are required for EBV infection (Connolly et al., 2011) .
gB is a type III transmembrane fusion protein that promotes merger of the viral and host membranes (Backovic et al., 2009 ). gB activity is dependent upon the heterodimeric gH/gL complex that acts as an adaptor that triggers gB-mediated fusion upon binding a cell-surface receptor on target cells (Mö hl et al., 2016; Stampfer and Heldwein, 2013) .
gH/gL assumes an elongated structure comprising four distinct domains designated D-I to D-IV. D-I is formed by gL and the N terminus of gH, whereas the rest of gH comprises D-II through D-IV (Matsuura et al., 2010) . D-I and D-II are separated by a prominent groove connected by a linker helix (Matsuura et al., 2010) . Mutations that affect membrane fusion have been identified throughout gH/gL, but most map to D-I and the DI/D-II interface, including the linker helix and the groove between D-I and D-II (Chen et al., 2013a; Mö hl et al., 2014; Omerovi c et al., 2005; Plate et al., 2011; Sathiyamoorthy et al., 2016; Wu et al., 2005) , indicating that this region of gH/gL is important for gB activation. avb5, avb6, or avb8 integrins (Chesnokova and Hutt-Fletcher, 2011; Chesnokova et al., 2009) , and the ephrin receptor A2 (EphA2) (Chen et al., 2018; Zhang et al., 2018) have been identified as epithelial cell surface receptors that interact directly with gH/gL to trigger gB-mediated fusion. An exposed Lys-Gly-Asp (KGD) motif on D-II has been proposed to mediate gH/gL binding to integrins (Chesnokova and Hutt-Fletcher, 2011; Chesnokova et al., 2009) , while the binding site of EphA2 on gH/gL is unknown.
B cell infection requires an additional viral glycoprotein, gp42, which forms a 1:1 complex with gH/gL (Kirschner et al., 2006) . The N terminus of gp42 mediates high-affinity interactions with gH/gL and the C terminus binds to the B chain of human leukocyte antigen (HLA) class II, which leads to triggering of gB-mediated fusion through the gH/gL-gp42 complex (Haan et al., 2000; Sathiyamoorthy et al., 2014; Spriggs et al., 1996) . Although gp42 is necessary for B cell infection, it inhibits epithelial cell infection (Kirschner et al., 2006 (Kirschner et al., , 2007 Wang et al., 1998) . Virions produced in B cells contain lower levels of gp42 than virions produced in epithelial cells. Thus, virions that shed from one cell type preferentially infect the other (Borza and Hutt-Fletcher, 2002) . gp350 is the most abundant EBV surface glycoprotein (Edson and Thorley-Lawson, 1981) . It promotes viral attachment to target cells through a high-affinity interaction with CD21 (Tanner et al., 1987) or CD35 (Ogembo et al., 2013) without mediating fusion. Anti-gp350 antibodies can inhibit B cell infection in vitro, but some enhance infection of CD21-negative epithelial cells (Turk et al., 2006) .
Sera from EBV-infected individuals can neutralize both B cell and epithelial cell infection in vitro (Miller et al., 1972; Moss and Pope, 1972; Sashihara et al., 2009; Tugizov et al., 2003) . However, the antigens and epitope specificities targeted by the corresponding neutralizing antibodies are not known. To date, only a handful of anti-EBV neutralizing monoclonal antibodies (MAbs) have been characterized, all of murine origin. The 72A1 mAb binds to the CD21/CD35 binding site on gp350 (Ogembo et al., 2013; Tanner et al., 1987) and potently neutralizes B cell infection (Hoffman et al., 1980; Sashihara et al., 2009) , but has no effect on infection of CD21-negative epithelial cells (Molesworth et al., 2000; Tugizov et al., 2003) . The C1 mAb binds to an unknown epitope on gp350 and inhibits B cell infection but promotes epithelial cell infection (Thorley-Lawson and Geilinger, 1980; Turk et al., 2006) . F-2-1 targets gp42 and inhibits B cell but not epithelial cell infection (Chesnokova and Hutt-Fletcher, 2011; Li et al., 1995; Molesworth et al., 2000; Strnad et al., 1982) . CL55 is the only EBV gB-specific mAb and it is non-neutralizing (Chesnokova and Hutt-Fletcher, 2011; Wu et al., 2005) .
E1D1, CL59, and CL40 bind gH/gL and neutralize epithelial cell infection but fail to efficiently block B cell infection (Balachandran et al., 1987; Chesnokova and Hutt-Fletcher, 2011; Li et al., 1995; Molesworth et al., 2000) . Mutagenesis and negative-stain electron microscopy (EM) studies have mapped the CL59 epitope to gH/gL D-IV (Sathiyamoorthy et al., 2017; Wu et al., 2005) .
High-resolution structures demonstrate that E1D1 binds exclusively to gL (Sathiyamoorthy et al., 2016) and that CL40 binds to an epitope at the D-II/D-III interface of gH (Sathiyamoorthy et al., 2017) , but the mechanisms by which they neutralize EBV infection have not been elucidated.
The isolation and structural characterization of neutralizing MAbs elicited during natural human infections with human immunodeficiency virus (HIV), influenza virus, respiratory syncytial virus, human cytomegalovirus (CMV), and dengue virus have defined critical epitopes on these pathogens and advanced vaccine design (Rappuoli et al., 2016) . To better characterize the humoral immune response to EBV, we sought to isolate antigen-specific memory B cells from EBV-infected individuals. We obtained several anti-gB antibodies one of which neutralized epithelial cell infection. We also isolated one anti-gH/gL antibody, called AMMO1, that potently neutralized both epithelial and B cell infection in vitro. Using a combination of cryo-electron microscopy (cyroEM) and X-ray crystallography, we determined the structure of the gH/gL-gp42-AMMO1 complex. This analysis demonstrated that AMMO1 binds to a discontinuous epitope on gH/gL at the interface between D-I and D-II, which is implicated in triggering gB-mediated fusion.
The isolation and characterization of AMMO1 described herein may help pave the way for the design of a gH/gL-based subunit vaccine. The dual-tropic inhibition of EBV entry by AMMO1 indicates that this mAb could also have therapeutic potential in blocking EBV infection, reactivation, and amplification in immunocompromised individuals and transplant recipients.
RESULTS

Anti-EBV Human Monoclonal Antibodies Isolated from Infected Individuals
We sought to isolate memory B cells specific for gp42, gp350, gH/gL, and gB using recombinant ectodomain glycoproteins as bait. All glycoproteins were recognized by known anti-EBV MAbs and serum antibodies from 15 out of 16 donors, indicating that they were properly folded and exhibited native antigenicity ( Figure S1 ).
We used phycoerythrin (PE) conjugated EBV glycoproteins to identify antigen-specific class-switched B cells. The majority stained positive with gp350 or gp42 ( Figure 1A ) due to their ability to bind CD21 (Tanner et al., 1987) and CD35 (Ogembo et al., 2013) or MHC class II (Haan et al., 2000; Spriggs et al., 1996) , respectively. Attempts to completely block non-specific gp350 and gp42 binding to these receptors with commercially available antibodies were unsuccessful and we did not pursue further efforts to sort these B cells.
B cell staining with gH/gL or gB was comparable to that with the unconjugated PE control ( Figure 1A ). This observation indicated that gH/gL-or gB-specific B cells are quite rare and led us to use complimentary approaches to isolate them. We employed a magnetic bead-based enrichment coupled with fluorescent decoy protein (Taylor et al., 2012) , which reduced background staining and allowed us to more confidently identify gH/gL-and gB-specific B cells ( Figure 1B ). Sorting was carried out starting with a total of 8 3 10 8 cryopreserved peripheral blood mononuclear cells from three separate donors (Table  S1 ). B cells were individually sorted into irradiated feeder cell cultures in the presence of recombinant cytokines. The supernatants were subsequently screened for antigen reactivity by ELISA. Despite the implementation of an enrichment step, most sorted cells were false positives and we identified only two gH/gL-and seven gB-positive wells (Table S1 ). From these, we successfully recovered paired variable heavy (VH) and variable light (VL) chain transcripts for one gH/gL antibody (AMMO1) and four gB-specific antibodies (AMMO2-AMMO5). All were derived from distinct heavy and light chain genes and displayed VH mutation frequencies ranging from 8%-10% and VK/VL frequencies ranging from $5%-8% at the nucleotide level ( Figure S3 ). We cloned the VH/VL sequences into recombinant expression vectors and verified by biolayer interferometry (BLI) that AMMO1 specifically bound to gH/gL, and that AMMO2-AMMO5 specifically bound to gB ( Figure 1C ). These results demonstrate that we have isolated human MAbs that target the EBV fusion machinery.
AMMO1 Inhibited EBV Infection of Both Epithelial and B Cells
We assessed the ability of AMMO1-AMMO5 to neutralize EBV infection of epithelial cells (Figure 2A ) and B cells ( Figure 2B ).
For comparison, we also included the murine anti-gH/gL MAbs CL40, CL59, and E1D1, which block epithelial cell infection but poorly inhibit B cell infection (Chesnokova and Hutt-Fletcher, 2011; Wu et al., 2005) . AMMO1, CL40, and CL59 had comparable potency in an epithelial cell infection assay, whereas E1D1 displayed incomplete neutralization at the highest concentration tested ( Figure 2A and Table S2 ). Among the anti-gB MAbs, AMMO5 neutralized EBV infection of epithelial cells, while AMMO2-AMMO4 were non-neutralizing ( Figure 2A and Table S2 ).
AMMO1 was the only anti-gH/gL MAb that completely neutralized B cell infection; it displayed comparable potency to the anti-gp350 MAb 72A1 ( Figure 2B and Table S2 ).
Despite not being completely neutralizing, CL40 was able to reduce B cell infection to 50%, but it was $100 times less potent than AMMO1 ( Figure 2B and Table S2 ). CL59 did not reproducibly achieve 50% neutralization, and E1D1 was completely ineffective at neutralizing B cell infection ( Figure 2B ). These results demonstrate that AMMO5 can prevent EBV infection of epithelial but not B cells, whereas AMMO1 can prevent infection of both cell types.
AMMO1 Recognized a Unique Discontinuous Epitope on gH/gL
To understand observed differences in the neutralization potency of AMMO1 and other anti-gH/gL MAbs, we determined their binding affinities for gH/gL. AMMO1 bound 1-2 orders of magnitude more tightly to gH/gL than other MAbs tested (Table  S3) . Although membrane fusion with Raji B cells can occur independently of endocytosis (Miller and Hutt-Fletcher, 1992 ), we measured binding at pH 5.0 to assess whether differences in the neutralization potency of B cell infection might result from exposure to the acidic endosomal compartment, which could affect antibody binding. Only E1D1 binding was affected by pH (Table S3) . Therefore, the higher potency of AMMO1 could not be attributed to dissociation of the other MAbs from gH/gL due to exposure to the low endosomal pH upon virion internalization.
Based on these results, we surmised that epitope differences may explain why AMMO1 is the only gH/gL MAb that completely neutralized infection of both B cells and epithelial cells. To delineate the AMMO1 epitope, we analyzed the gH/gL-gp42-AMMO1 complex by cryoEM ( Figures 3A, 3B , S4, and Table S4 ). We determined a reconstruction of the complex at 4.8 Å resolution, which resolved secondary structural elements and several amino acid side chains as well as densities corresponding to N-linked glycans on gH, gL, and gp42. The local resolution varied between $4 Å in the region of the map corresponding to the gH core and 4.5-6.0 Å for gL, gp42, and AMMO1 ( Figure S4 ). We also determined a 1.6 Å crystal structure of the unliganded AMMO1 antigen binding fragment (Fab , Table S5 ) and generated a model of the gH/gL-gp42-AMMO1 complex using Rosetta (DiMaio et al., 2015) and available EBV glycoprotein structures (Figures 3C and 3D and Table S4 ; Matsuura et al., 2010; Sathiyamoorthy et al., 2016). The architecture of gH/gL-gp42 in the complex is in good agreement with the gH/gL-gp42-E1D1 crystal structure (Ca root mean square deviation of 1.1 Å over 915 aligned residues of gH/gL-gp42) (Sathiyamoorthy et al., 2016) .
AMMO1 bound to a discontinuous epitope spanning gH/gL D-I and D-II, which comprised residues of both gH and gL, burying a surface area of 1,160 Å 2 ( Figures 3E and 3F ). CDRL2, CDRH1, and CDRH3 contacted the 2a-4 helix ( Figures 3E and 3F ). CDRH3 also bound the short helix between the 2b-7 and 2b-8 strands and the loop between 2a-1 and 2b-1. CDRL1 bound to the gH/gL interface, contacting the gH 2a-1 linker helix between D-I/D-II, and the gL C-terminal La-3 helix ( Figures 3E and 3F) .
We introduced several mutations in gH and gL at residues, which were predicted to contact AMMO1 and assessed binding of the MAb to cell surface expressed gH/gL ( Figure S5 ). When mutated to alanine, two residues, K73 and Y76 in the 2a-1 linker helix, led to a reduction in AMMO1 binding ( Figures S5D and 3F) . Substitution of K73 with a bulkier tryptophan residue virtually abrogated AMMO1 binding ( Figure S5D ), as predicted by the atomic model.
The N-linked glycan on gH-N60 is oriented such that it could putatively contact the AMMO1 CDRL2 and framework region ( Figure 3G ). We profiled N-linked glycosylation in gH, gL, and gp42 by mass-spectrometry, which verified the presence of various glycans at gH-N60 ( Figure S4H and Data S1). A gH-T62A substitution, which disrupts the N60 glycosylation sequon, altered AMMO1 binding kinetics, which indicated that the glycan could interact with the antibody (Table S3 ). The first residue of the AMMO1 heavy chain, a pyroglutamic acid, appeared to interact directly with the gp42 C-domain (CTD). Substitution of this residue by an asparagine did not substantially affect the neutralization potency of AMMO1 ( Figure S6 ) or its affinity for gH/gL (Table S3) .
Our cryoEM structure indicated that the AMMO1 epitope was distinct from that of E1D1 and CL59, which bind exclusively to gL and to D-IV, respectively (Sathiyamoorthy et al., 2016 (Sathiyamoorthy et al., , 2017 . Comparison of the gH/gL-gp42-AMMO1 cryoEM structure with the gH/gL-gp42-N-terminal domain-CL40 crystal structure (Sathiyamoorthy et al., 2017) showed not only that the epitopes of the two antibodies overlap at the 2a-4 helix, but also that their Fab fragments would clash upon binding to gH/gL ( Figures  4A-4C ). To confirm this observation and assess whether AMMO1 affects the binding of other anti-gH/gL MAbs, we performed reciprocal competitive binding experiments using BLI. In agreement with the structural data, we observed reduced binding of immobilized AMMO1 to gH/gL when an excess of soluble CL40 was present ( Figure 4D , green trace) and complete inhibition of CL40 binding to gH/gL in the presence of an excess of AMMO1 ( Figure 4E , red trace). We detected an increase in the nm shift for the other combinations of gH/gL-MAbs, consistent with the formation of higher-molecular weight complexes (Figures 4F and 4G) . Collectively, these results demonstrate that AMMO1 binds to a unique epitope on gH/gL that is distinct from that of CL59 and E1D1 but partially overlaps with the CL40 epitope.
A Clash Between the gp42 N173 Glycan and AMMO1 Can Displace the gp42 CTD CL40 was reported to displace the gp42 CTD upon binding to the gH/gL-gp42 complex as a consequence of the overlap of their interaction sites on gH/gL (Sathiyamoorthy et al., 2017) . Although the footprints of AMMO1 and gp42 are distinct, gH residue N240 experienced a change of accessible surface area upon binding to either of these two proteins ( Figure 5A ). Since AMMO1 and gp42 are located on opposite sides of this residue, their interactions with N240 do not appear mutually exclusive ( Figure 5B ). Using a distinct subset of particles identified by three-dimensional classification of the cryoEM dataset, we obtained a second reconstruction of the gH/gL-gp42-AMMO1 complex at 10 Å resolution in which the gp42 C-domain density is displaced relative to gH/gL ( Figures 5C, 5D , and S4G).
Two-dimensional classification of negatively stained gH/gLgp42-AMMO1 complexes ( Figures S7B-S7C ) also showed that a fraction of AMMO1-bound complexes had a displaced gp42 CTD ( Figure S7C ). In contrast, gp42 was displaced from all gH/gL-gp42-CL40 complexes under the same conditions ( Figure S7D ).
In the 4.8 Å cryoEM map, the gp42-N173 glycan points toward the framework region of the AMMO1 light chain indicating that it might interfere with AMMO1 binding ( Figure 5E ). Using mass spectrometry, we verified the presence of various glycans at this position ( Figure S4H and Data S2). In line with these observations, binding experiments revealed partial competition between AMMO1 and gp42 for binding to gH/gL ( Figure 5F , left). This competition was abrogated by the introduction of a T175A mutation, which disrupts the N173 glycosylation sequon ( Figure 5F , right). These data revealed that AMMO1 can sterically displace the gp42 CTD from gH/gL through the gp42 N173 glycan.
AMMO1 Blocks Membrane Fusion
Although AMMO1 could alter the conformation of gp42 in the gH/gL-gp42 complex, binding to HLA class II was unaffected by the presence of the AMMO1 Fab ( Figure 6A ). We also assessed whether AMMO1 binding to gH/gL-gp42 could affect the ability of the complex to bind to B cells. As expected, gH/gL bound to Raji cells in the presence of gp42 ( Figure 6B ). An excess of AMMO1, but not CL40 or the control MAb AMMO4, reduced but did not completely inhibit gH/gL-gp42 binding to B cells ( Figure 6B ).
During epithelial cell infection, gH/gL binds directly to receptors on the surface of epithelial cells that presumably trigger it and lead to the subsequent activation of gB (Borza et al., 2004; Chen et al., 2012) . We observed weak binding of gH/gL to the surface of the AGS epithelial cell line ( Figure 6C ). Pre-incubation with AMMO1, CL40, or gp42 reduced but did not abrogate gH/gL binding to AGS cells ( Figure 6C ), whereas the anti-gB MAb AMMO4 had no effect.
gH/gL is thought to interact directly with avb5, avb6, or avb8 integrins present at the surface of epithelial cells through the KGD motif on gH D-II Chesnokova and Hutt-Fletcher, 2011; Chesnokova et al., 2009 ). Our results suggested that AMMO1 binding could restrict integrin access to the KGD motif due to the proximity of its epitope ( Figure 3G ). We were unable to detect binding of gH/gL to avb5, avb6, or avb8 integrins ( Figure 6D ). These observations are in line with a recent report (Sathiyamoorthy et al., 2017 ), but contrast with previous studies (Chesnokova and Hutt-Fletcher, 2011; Chesnokova et al., 2009) .
A direct interaction between gH/gL and EphA2 has recently been shown to be important for EBV viral entry (Chen et al., 2018; Zhang et al., 2018) . We observed a very weak binding signal between EphA2 and gH/gL that was unaltered by pre-incubation of AMMO1 ( Figure 6E ), suggesting that AMMO1 does not prevent a gH/gL-EphA2 interaction.
The observation that AMMO1 potently neutralized EBV infection of both B cells and epithelial cells pointed to a common mechanism of viral inhibition. Because AMMO1 fails to completely block binding of gH/gL to epithelial cells or gH/gLgp42 to B cells, we hypothesized that AMMO1 is likely interfering with gB activation and membrane fusion. Using a virus-free cell fusion assay (McShane and Longnecker, 2005) , we observed that the anti-gH/gL MAbs AMMO1 and CL40 and the anti-gB MAb AMMO5 significantly reduced cell fusion, whereas the non-neutralizing MAb AMMO3 had no effect ( Figure 6E ). Collectively these results indicated that AMMO1 can restrict gH/gL or gH/gL-gp42 access to cell surface receptors and that it is capable of blocking membrane fusion.
DISCUSSION
Orally transmitted EBV establishes infection in permissive cells in the oral mucosa such as epithelial cells or infiltrating B cells (Rickinson et al., 2014; Taylor et al., 2015) . EBV has tropism for both cell types and it is not clear which one is preferentially infected during primary infection (Tangye et al., 2017) . The virus could first infect epithelial cells and lytic viral replication would subsequently seed B cell infections. Alternatively, the virus may initially infect infiltrating B cells, which would lead to subsequent targeting of epithelial cells. Neither scenario is mutually exclusive; thus a combination of epithelial and B cell neutralizing antibodies may be required to most effectively block incoming virus at the oral mucosa (Herrman et al., 2015) .
gp350 MAbs can inhibit infection of B cells but not CD21-negative epithelial cells. Conversely, anti-gH/gL MAbs are effective at preventing epithelial cell infection but fail to prevent B cell infection. These observations suggest that gp350 or gH/gL antibodies alone might not be sufficient to prevent EBV infection and that an effective EBV subunit vaccine might need to elicit both types of antibodies to prevent an initial infection event.
Previous EBV subunit vaccine studies in humans focused on gp350. Recombinant gp350 elicits antibodies that can neutralize B cell infection in vitro Sokal et al., 2007) . Although a phase II clinical trial of a gp350 subunit vaccine showed clinical benefit by reducing the incidence of infectious mononucleosis, it failed to protect from EBV infection . From these results emerged the idea that the efficacy of EBV subunit vaccines could be improved if they were formulated with additional glycoproteins (Cohen et al., 2013) . The potent in vitro neutralizing activity of AMMO1 suggests that a gH/gL-based vaccine capable of eliciting AMMO1-like antibodies could be as effective as gp350 at blocking EBV entry into B cells, while also preventing epithelial cell infection. Moreover, a gH/gL vaccine would avoid the potential enhancement of epithelial cell infection reported for anti-gp350 antibodies (Turk et al., 2006) . In support of this notion, rabbit immunization with gH/gL elicited higher antibody titers blocking B cell infection than gp350 (Cui et al., 2016) .
AMMO1 may also have utility as a therapeutic agent. Passive administration of the 72A1 MAb demonstrated potential to prevent EBV infection during the early post-transplant period in high-risk EBV-seronegative transplant recipients. However, administration of 72A1 led to the production of anti-drug antibodies, which were attributed to its murine origin (Haque et al., 2006) . Because AMMO1 can neutralize infection of the two main cell types targeted by EBV and is human derived, it may present a more effective and safer alternative than 72A1.
The unique ability of AMMO1 among anti-gH/gL MAbs to neutralize both epithelial and B cell infection points to a common mechanism of neutralization, most likely by interfering with gB triggering. Mutagenesis studies identified that the D-I/D-II linker region is key for membrane fusion (Omerovi c et al., 2005) . Several of these critical residues are buried by AMMO1. Thus, AMMO1 could inhibit fusion activation by preventing direct interaction between gB and the linker-helix on gH/gL ( Figure 7A ). Residues within the D-I/D-II groove were shown to mediate membrane fusion as well (Chen et al., 2013a; Matsuura et al., 2010; Plate et al., 2009) , suggesting that conformational changes within the D-I/D-II groove might be required for triggering of, or interaction with gB (Chen et al., 2013a; Chesnokova and Hutt-Fletcher, 2011) . Since AMMO1 binds to elements of D-I (including gL), D-II, and the linker helix, it could inhibit gB activation by acting as a molecular clamp preventing movements within and across D-I and D-II ( Figure 7B ).
The architecture of CMV gH/gL resembles that of EBV gH/gL (Chandramouli et al., 2017) . It has been proposed that binding of the CMV gH/gL/UL128/UL130/UL131 pentamer to a cell surface receptor induces a D-I rearrangement around the linker helix, which leads to a widening of the D-I/D-II groove and gB triggering (Chandramouli et al., 2017) . Thus, the linker helix may be a target for antibodies that neutralize CMV infection as well. The mAb 13H11, which neutralizes CMV infection of both epithelial cells and fibroblasts, binds in proximity of the CMV gH/ gL linker helix, although higher-resolution data will be needed to compare the 13H11 and AMMO1 binding modes (Ciferri et al., 2015; Macagno et al., 2010) .
The proposed fusion inhibition activity of AMMO1 is further supported by studies of neutralizing MAbs against gH/gL from other herpesviruses. MAbs that inhibit fusion of varicella zoster virus bind to epitopes bridging the first two domains of gH/gL (Xing et al., 2015) . Escape mutations from the LP11 antibody, which blocks the herpes simplex virus gH/gL-gB interaction, also map to a similar epitope region on gH/gL (Chowdary et al., 2010) .
Previous studies suggest that displacement of the gp42 CTD by CL40 prohibits a conformation of the gH/gL-gp42-HLA class II complex necessary for triggering gB-mediated fusion during B cell infection (Sathiyamoorthy et al., 2017) . The observation that CL40 more readily displaces gp42 than AMMO1 but fails to potently neutralize B cell infection indicated that this is (D) A fraction of particle images are characterized by a displacement of the gp42 C-domain. The map is shown at high contour (isosurface) and at low contour (mesh) level to demonstrate that the gp42 CTD is much less well ordered than the rest of the complex. (E) The 4.8 Å resolution reconstruction shown in (C) reveals that the gp42 N173 glycan points toward the AMMO1 framework region. The glycan is rendered in stick representation with the corresponding region of cryoEM density (blue mesh). (F) AMMO1 binding to gH/gL pre-incubated with the indicated concentrations of gp42 (left) or gp42-T175A (right) was measured by BLI. Representative curves from two independent replicates are shown in (F). See also Figures S4 and S7 .
not the primary mechanism of B cell neutralization by AMMO1. Future studies that shed light on the elusive nature of the gH/gL-gB interaction will be necessary to determine whether and how AMMO1 disrupts gB function.
Our data also indicated that AMMO1 could contribute to neutralization by restricting access of gH/gL or gH/gL-gp42 to cell surface receptors during epithelial and B cell infection, respectively ( Figures 7C and 7D) . aVb5, aVb6, and aVb8 integrins (Chesnokova and Hutt-Fletcher, 2011; Chesnokova et al., 2009) and EphA2 (Chen et al., 2018; Zhang et al., 2018) have been implicated as cell surface EBV receptors during epithelial cell infection. AMMO1 did not affect EphA2 binding to gH/gL, so it is unlikely that AMMO1 inhibits EBV infection of epithelial cells by blocking this interaction.
Although we could not detect an interaction between gH/gL and soluble aVb5, aVb6, or aVb8 integrins by BLI, the reduced binding of gH/gL to epithelial cells in the presence of AMMO1 indicates that the MAb may restrict binding to cell-surface anchored integrins, to membrane anchored EphA2, or to an alternative receptor ( Figure 7D ).
In this study, we also isolated AMMO5, an anti-gB MAb that could inhibit entry into epithelial cells. The inability of AMMO5 to antagonize B cell infection points to putative differences in gB triggering and/or fusion during EBV entry into the two cell types. This notion is supported by mutagenesis studies of gH/gL, which revealed distinct effects on fusion with B cells and with epithelial cells (Chen et al., 2013a; Mö hl et al., 2014; Sathiyamoorthy et al., 2016; Wu et al., 2005) .
Most of the anti-gB MAbs isolated in this study were nonneutralizing. We emphasize that the gB protein used to sort B cells is most likely in the post-fusion conformation (Backovic et al., 2009 ) and might fail to bait out neutralizing antibodies recognizing the pre-fusion state, as was reported for the RSV fusion protein (Magro et al., 2012; McLellan et al., 2013) .
In summary, we report the isolation of anti-EBV neutralizing antibodies arising from natural infection in humans and identify the anti-gH/gL antibody AMMO1 that potently neutralizes both epithelial and B cell infection. The near-atomic resolution cryoEM structure of the gH/gL-gp42-AMMO1 complex presented here defines a key site of EBV vulnerability and may help pave the way for the design of next-generation subunit vaccines. The moderate level of somatic mutation in AMMO1 is within the range that could be elicited with current human vaccine regimens implemented for influenza or HIV (Easterhoff et al., 2017; Joyce et al., 2016; Moody et al., 2011; Wrammert et al., 2008) . Because AMMO1 is of human origin, it could also be used to treat and/or prevent EBV-related complications such as lymphoproliferative diseases in organ transplant recipients and immunocompromised individuals.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Human Subjects
Peripheral blood mononuclear cells (PBMC) and serum were collected from seven HIV-uninfected, and eight HIV-infected adults recruited at the Seattle HIV Vaccine Trials Unit (Seattle, Washington, USA) as part of the study ''Establishing Immunologic Assays for Determining HIV-1 Prevention and Control,'' also referred to as Seattle Assay Control or SAC. All participants signed informed consent, and the following institutional human subjects review committee approved the protocol prior to study initiation: Fred Hutchinson Cancer Research Center IRB (Seattle, Washington, USA). PBMC samples from donors were blindly selected at random with no considerations made for age, or sex.
Cell lines
All cell lines were incubated at 37 C in the presence of 5% CO 2 and were not tested for mycoplasma contamination. 293T (human female) and NIH 3T3 (murine male) cells were grown in DMEM containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (cDMEM). CHO K-1 (hamster female) and AGS (human female) cells were maintained in Ham's F-12 + 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (cF-12). Raji cells (human male), as well as the 72A1 (murine sex unknown), CL55(murine sex unknown), (Wu et al., 2005) , F-2-1 (murine sex unknown), (Strnad et al., 1982) , CL40 (murine sex unknown), CL59 (murine sex unknown), (Molesworth et al., 2000) , and E1D1 (Balachandran et al., 1987) hybridomas, were maintained in RMPI + 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (cRPMI). 293-2089 cells (human female) (Delecluse et al., 1998) were grown in cRPMI containing 100mg/ml hygromycin. AKATA (human female) B cells harboring EBV in which the thymidine kinase gene has been replaced with a neomycin and GFP cassette virus (AKTA-GFP) (Molesworth et al., 2000) , were grown in cRMPI containing 350mg/ml G418. SVKCR2 cells (human male) (Li et al., 1992) were grown in DMEM containing 10% cosmic calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin, 10 ng/ml cholera toxin and 400 mg/ml G418. 293-T7 cells (human female) (Omerovi c et al., 2005) were maintained in cDMEM containing 100mg/ml Zeocin. 293F (human female) cells were maintained in Freestyle 293 media with gentle shaking.
METHOD DETAILS
Plasmids cDNA encoding to gH (AA 19-679, GenBank AFY97969.1), gp42 (amino acids 33-223, GenBank: AFY97939.1), gp350 (AA 1-470, GenBank: AAD51697.1), and gB AA 23-683, GenBank: AFY97983.1) with the residues WY 112-113 mutated to mutated to RVEA (QA Backovic et al., 2007) were synthesized with an N-terminal TPA leader peptide (MDAMKRGLCCVLLL CGAVFVSPSAS) and a C-terminal HIS-Avi Tag (GSGSGHHHHHHGLNDIFEAQKIEWHE) and cloned into the EcoRI and NotI sites of the pTT3 plasmid. gL (AA 24-137 GenBank: AFY97944.1), was synthesized with an N-terminal TPA leader peptide (MDAMKRGLCCVLLLCGAVFVSPSAS) without a C-terminal tag and cloned into the EcoRI and NotI sites of the pTT3 plasmid. Site directed mutagenesis was used to introduce stop codons into gH and gp42 between the HIS and Avi tags to produce expression plasmids without the Avi-Tag, and to introduce the T62A and T175A mutations into gH and gp42, respectively. The murine CD40L sequence flanked by an XbaI-Kozak sequence on the 5 0 end and a Not I site on the 3 0 end was synthesized by Genscript and cloned into the XbaI and NotI sites of pCDH-EF-MCS-IRES-RFP vector (Systembio) to create pCDH-muCD40L-RFP.
pCAGGS expression plasmids for gH, gL, gB, and pT7EMCLuc (which carries a luciferase-containing reporter plasmid under the control of the T7 promoter) were kindly provided by Dr. R. Longnecker (Haan et al., 2001; Okuma et al., 1999; Plate et al., 2011) . Plasmids for the expression of humanized, recombinant 72A1 were provided by Dr. F. Wang (Herrman et al., 2015) . p509, an expression plasmid encoding BZLF1, was provided by Dr. W. Hammerschmidt (Delecluse et al., 1998) . p2670, an expression plasmid encoding BALF4, was provided by Dr. H. Delecluse (Neuhierl et al., 2002) .
Recombinant Antibody Cloning
Codon optimized cDNAs encoding a murine leader sequence MGWSCIILFLVATATGVHS followed by the human IgG1, IgL or IgK constant regions were synthesized by IDT and cloned into the EcoRI and BamHI sites of pTT3. VH and VL sequences recovered from sorted B cells using RT PCR (see below) were amplified with gene-specific primers or synthesized by IDT and assembled in frame into the appropriate linearized IgG IgK or IgL plasmid using InFusion cloning. The sequences of the recombinant antibody plasmids were verified by Sanger sequencing.
Recombinant Protein Expression
Plasmids encoding EBV proteins, or antibody heavy and light chains were transfected into 293F cells at a density of 10 6 cells/ml in Freestyle 293 media using the 293Free transfection reagent according to the manufacturer's instructions. Expression was carried out in Freestyle 293 media for 6 days after which cells and cellular debris were removed by centrifugation at 4,000 3 g followed by filtration through a 0.22 mm filter. Clarified cell supernatant containing EBV proteins was passed over Ni-NTA resin pre-equilibrated with Ni-NTA binding buffer (0.3 M NaCl, 20 mM Tris,10mM imidazole, pH 8.0), followed by extensive washing with Ni-NTA binding buffer, and then eluted with 250 mM imidazole, 0.3 M NaCl, 20 mM Tris, pH 8.0 (Ni-NTA elution buffer). Purified proteins were then dialyzed overnight into PBS. AVI-tagged gB, gp350, and gp42 were biotinylated in vitro using the In Vitro Biotin Ligase Kit.
Proteins were further purified by size exclusion chromatography (SEC) using a 10/300 Superdex 200 column (GE Healthcare) equilibrated into HBSE (10 mM HEPES, 150 mM NaCl, 2 mM EDTA pH 7.4), which also served to remove un-ligated biotin and BirA enzyme. Biotinylated proteins were flash frozen and stored at À20 C until use. Clarified cell supernatant containing recombinant antibodies was passed over Protein A Agarose, followed by extensive washing with PBS, and then eluted with 1 mL of Pierce IgG Elution Buffer, pH 2.0 into 0.1 mL of Tris HCl, pH 8.0. Purified antibodies were then dialyzed overnight into PBS.
Recombinant Protein Biotinylation AMMO1, E1D1, CL40, CL59, and gH/gL were biotinylated at a theoretical 1.5:1 biotin/protein with the EZ-Link Sulfo-NHS-Biotin Kit. Free biotin was removed by 3 successive rounds of dilution with PBS and concentration with a 30,000 MCOW concentrator (Amicon).
Antigen Binding Fragment Preparation AMMO1 Fab was produced by digesting AMMO1 IgG with Endoproteinase Lys-C overnight at 37 C (10 mg IgG: 1ng Lys C). Fab fragments were separated from Fc fragments with protein A agarose, then further purified with SEC. CL40 Fab was produced by digesting CL40 IgG with activated immobilized ficin at 37 C for 48 hr. Fab fragments were separated from Fc fragments with protein A agarose, then further purified by SEC.
3T3-CD40L Cell Line Generation
Lentiviruses were produced by co-transfecting the pCDH-muCD40L-RFP, psPAX2 and pMD2.G plasmids at a 4:2:1 ratio (6, 3, and 1.5 mg, respectively) into 293T cells using the GeneJuice Transfection Reagent. 48 hours later the supernatant was collected and passed through a 0.22 mm filter. Supernatant was then transferred to 3T3 cells followed by the addition of 4 mg/ml polybrene and incubated overnight in cDMEM. Cells were then passaged for 7 days. CD40L-expressing cells were identified with a PE-labeled CD154 antibody and sorted by FACS on a Beckman FACS AriaII. Sorted cells were expanded and cultured indefinitely.
Biolayer Interferometry (BLI) BLI assays were performed on the Octet Red instrument at 30 C with shaking at 1,000 RPM. Validation of EBV glycoprotein antigenicity using murine hybridomas: Anti-EBV antibodies were captured using Anti-Mouse IgG Fc capture (AMC) biosensors (Fortebio) by immersing sensors directly into hybridoma culture supernatants for 600 s. A baseline signal was recorded for 1 min in kinetics buffer (KB: 1X PBS, 0.01% BSA, 0.02% Tween 20, and 0.005% NaN 3, ) at pH 7.4. Sensors were then immersed into solutions containing a 0.5mM concentration of each EBV glycoprotein for 250 s to measure association, followed by immersion in KB for 500 s to measure dissociation. All measurements of antibody binding were corrected by subtracting the signal obtained from simultaneous traces performed with the corresponding envelopes in the absence of antibody, using PBS only.
Kinetic analysis: Anti-Human IgG Fc capture (AHC) sensors (for human antibodies), AMC (for murine antibodies), or streptavidin sensors (for biotinylated antibodies or biotinylated gH/gL or gH T62A/gL) were immersed in KB containing 10 mg/ml of purified antibody or biotinylated protein for 200 s. After loading, the baseline signal was then recorded for 1 min in KB. The sensors were immersed into wells containing serial dilutions of purified recombinant gH/gL or gH-T62A/gL in KB for 250 s (association phase), followed by immersion in KB for an additional 750 s (dissociation phase). The background signal from each analyte-containing well was measured using empty reference sensors, and subtracted from the signal obtained with each corresponding ligand-coupled sensor. The background signal of ligand-coupled sensors in KB was subtracted from each sensor at each time-point. Kinetic analyses were performed at least twice with an independently prepared analyte dilution series. Curve fitting was performed using a 1:1 binding model and the ForteBio data analysis software. Mean k on , k off values were determined by averaging all binding curves that matched the theoretical fit with an R 2 value of R 0.99. Binding analyses at pH 5.0 were carried out as above in KB buffer at pH5.0 using biotinylated antibodies and Streptavidin sensors.
Antibody competition binding assays: Biotinylated antibodies were diluted to 10 mg/ml and captured onto streptavidin sensors for 120 s. The baseline interference was then read for 60 s in KB buffer, followed by immersion for 250 s (association phase) in a 250 nM solution of gH/gL alone, or gH/gL that had been pre-incubated with 500 nM of non-biotinylated Abs for 20 min in KB. Sensors were then immersed in KB for 750 s (dissociation phase).
gH/gL/gp42-HLA-DR binding assays: Biotinylated gH/gL was immobilized on streptavidin biosensors, and then immersed into KB buffer for 60 s followed by into a 1 mM solution of gp42 for 200 s. One biosensor was then immersed into a 1 mM solution of the AMMO1 Fab, while the other was immersed in KB for 200 s. The biosensors were then immersed into a 500 nM solution of HLA-DR for 300 s (association phase) and then into KB for 300 s (dissociation phase). One gH/gL-gp42 loaded sensor was immersed in buffer as a reference during the association and dissociation steps and used to subtract the background signal.
gH/gL-integrin binding assays: Biotinylated gH/gL was diluted to 10 mg/ml and captured onto streptavidin sensors for 120 s. The baseline interference was then read for 60 s in KB buffer containing followed by immersion for 200 s (association phase) into KB buffer containing 1 mM of avb5, avb6, avb8, gp42, or an HIV-1 Envelope protein (426c TM 4 DV1-3 (McGuire et al., 2016) ). Sensors were then immersed in KB containing for 400 s (dissociation phase).
gH/gL EphA2 binding assays: Biotinylated gH/gL was diluted to 30 mg/ml and immobilized on streptavidin biosensors for 120 s, and then immersed in KB buffer for 60 s. Biosensors were then immersed into either KB buffer or into a 1.5 mM solution of AMMO1 for 60 s. The biosensors were then immersed into a 3.5 mM solution of EphA2 for 250 s (association phase) and then into KB for 250 s (dissociation phase). To control for non-specific binding due to the high analyte concentration, we subtracted the binding signal to biotinylated gp42 immobilized on biosensors assayed under identical conditions. Serum ELISA 50 ng/well of gp350, gp42 or gB, were adsorbed onto 96 well Immulon 2HB ELISA plates at either 37 C for 1 hour or room temperature overnight in a solution of 0.1 M NaHCO 3 pH 9.4-9.6. Plates were then washed 4 times with ELISA washing buffer (1 3 PBS, 0.02% Tween 20) prior to blocking at 37 C for 1 hour or 4 C overnight with 250 ml per well of PBS containing 10% Non-Fat Milk and 0.02% Tween 20 (blocking buffer). After blocking, plates were washed 4 3 with ELISA washing buffer. Serum was diluted in blocking buffer and three-fold serial dilutions were performed in duplicate followed by a 1 hour incubation at 37 C. Following 4 additional washes with ELISA washing buffer, a 1:3000 dilution of goat anti-human Ig HRP in blocking buffer was added to each well and incubated at 37 C for 1 hour followed by 4 washes with wash buffer. 50 ml/well of SureBlue Reserve TMB Microwell Peroxidase substrate was added. After 3 min, 50 ml/well of 1N Sulfuric Acid was added and the A 450 of each well was read on a Molecular Devices SpectraMax M2. Analysis was performed using the Prism 6 package (Graphpad Software). ELISAs against gH/gL were performed essentially the same as above except for the following changes: 100 ml/well of a 1 mg/ml solution of His-tagged gH/gL was immobilized on Nickel Coated Plates in 1 3 PBS and 0.5% Tween 20 overnight at 4 C. The blocking buffer consisted of PBS containing 10% Non-Fat Milk, 0.02% Tween20, and 10 mM imidazole. The background of serum reactivity with the nickel-coated plates of each donor's sera was subtracted from that of gH/gL at each serum dilution.
Conjugation of Antigens to Fluorescently Labeled Streptavidin
Biotinylated EBV glycoproteins were mixed with streptavidin-phycoerythrin (SA-PE) at a 4:1 biotin to streptavidin ratio.
B Cell Sorting
Cryopreserved PBMC were thawed into cRMPI, at a concentration of 4 million PBMC/ml, followed by centrifugation at 300 3 g for 5 min. Cells were suspended in $100ml cRPMI and incubated with an irrelevant, Avi-tagged recombinant decoy protein from Plasmodium yoelii (PY-gamma, a kind gift from Dr. D.N. Sather) conjugated to streptavidin PE labeled with Dylite 650 (SA-PE-DL650) to a final concentration of 10 nM of PE-DL650 for 10 min at 4 C. Antigen (gB, gH/gL, gp42, or gp350) conjugated to SA-PE was then added to a final concentration of 10nM and incubated for 20 min at 4 C. 25 ml of Anti-PE MicroBeads (Miltenyi Biotech) were added and incubated for an additional 30 min at 4 C. The cell/bead mixture was then passed over a LS MACS separation column (on a MACS separator and washed with 6 mL of FACS buffer (PBS + 1% FBS). The column was removed from the MACS separator and eluted two times with 5 mL of FACS buffer. PE-enriched PBMC were then pelleted by centrifugation at 300 3 g for 5 min, and then re-suspended in 100 ml of FACS buffer. Enriched PBMC were then stained with the following antibodies: IgM-FITC at a 1:20 dilution, IgD-PerCP-Cy5.5 at a 1:100 dilution, CD27-PE-Cy7 at a 1:200 dilution, CD20-eF450 at a 1:100 dilution, CD3-BV711 at a 1:100 dilution, CD14-BV711 at a 1:100 dilution, CD16-BV711 at a 1:100 dilution, CD19-BV786 at a 1:100 dilution, and a fixable viability dye eFluor 506 at a 1:200 dilution for 25 min at 4 C. Stained cells were diluted to 5 mL with FACS buffer, pelleted by centrifugation at 300 3 g for 5 min and then suspended in 0.5 mL of FACS buffer and subjected to FACS on a BD FACS Aria II.
Live, antigen-positive class-switched B cells (Live/dead-, CD3-, CD14-, CD16-, CD19+ CD20+ IgM-, IgD-, PE-DL650-, PE+) were sorted individually into 96 well plates containing 2.86 3 10 4 irradiated 3T3-CD40L cells in 100 ml/well IMDM containing 10% FBS, 1 3 glutamax, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 U/ml IL2 and 50 ng/ml IL21 (Huang et al., 2013) . Cells were cultured at 37 C, 5% CO 2 . 13 days later the 80 mL of supernatant was transferred into 96 well round-bottom plates. 20 ml of lysis buffer (15 mM Tris pH 8.0, containing RNase inhibitor) was added to the wells containing cells. The cells were then frozen on dry ice and stored at À80 C.
Sorted Cell Supernatant Screening
Nunc 384 well MaxiSorp plates were coated overnight at room temperature with 50 ml of a 0.5 mg/ml solution of unlabeled goat anti human IgG or gB, in 0.1 M NaHCO 3 pH 9.4-9.6. 100 ml/well of a 1 mg/ml solution of His-tagged gH/gL was immobilized 96 well nickel coated plates in 1 3 PBS and 0.5% Tween 20 overnight at 4 C. ELISA plates were then washed 4 3 with ELISA wash buffer, and cell supernatant diluted 1:1 with blocking buffer was then added to the appropriate wells (one well per antigen). ELISA was performed as described under ''Serum ELISA,'' except that all volumes were halved in the 384 well plates. Wells were scored as positive if the A 450 was > 2 standard deviations of the A 450 recorded with the feeder cell only control supernatants (n = 4 wells).
VH/VL Recovery from Sorted Cells
Wells containing sorted cells that were antigen positive by ELISA were thawed and 15 ml of cell lysate was transferred to a thin wall PCR tube and mixed with 10 ml of reverse trasnscription (RT) mix containing 5 ml of first strand buffer, 1.25 ml of 100 mM DTT, 0.06 ml of IGEPAL, 125 ng of random hexamers, 2 ml of 10 mM dNTP mix, 0.5 ml of RNase inhibitor, and 1 mL of superscript III reverse transcriptase. RT was carried out at 42 C for 10 min, 25 C for 10 min, 50 C for 60 min, and 94 C for 5 min, followed by a hold at 4 C. 3 ml of cDNA was used as a template for a two-step nested VH, VK, or VL amplification using the primer set and protocol developed by Doria-Rose and colleagues (Doria-Rose et al., 2015) . VH and VL amplicons were Sanger sequenced and then cloned into recombinant expression vectors and expressed as recombinant IgG 1 proteins.
Virus Production
To produce B cell tropic GFP reporter viruses (B95-8/F), 9 3 10 6 293-2089 cells were seeded on a 15 cm tissue culture plate in cRPMI containing 100 mg/ml hygromycin. 24 hours later the cells were washed 2 3 with PBS, media was replaced with cRMPI without hygromycin, and the cells were transfected with 15 mg of each of p509 (Delecluse et al., 1998) and p2670 (Neuhierl et al., 2002) expressing BZLF1 and BALF4, respectively, using GeneJuice transfection reagent. 72 hours later the cell supernatant was collected, cell debris removed by centrifugation at 300 3 g for 5 min and then passed through a 0.8 mm filter. To produce epithelial cell tropic virus, B cells harboring AKATA-GFP EBV were suspended at 4 3 10 6 cells/ml in RPMI containing 1% FBS. Anti-human IgG was added to a final concentration 100 mg/ml and incubated at 37 C for 4 hours. Cells were then diluted to 2 3 10 6 cells/ml in RPMI containing 1% FBS and incubated for 72 hours. Cells were pelleted by centrifugation at 300 3 g for 10 min and then the supernatant was passed through a 0.8 mm filter. Bacitracin was added to a final concentration of 100 mg/ml. Virions were concentrated 25 3 by centrifugation at 25000 3 g for 2 hours and re-suspended in RPMI containing 100mg/ml bacitracin. Virus was stored at 4 C for up to 2 weeks.
B Cell Neutralization Assay B cell neutralization assays were carried out in Raji cells essentially as described (Sashihara et al., 2009) . Monoclonal antibodies were serially diluted in duplicate wells of 96 well round-bottom plates containing 25 ml of cRPMI in duplicate. 12.5 ml of B95-8/F virus (diluted to achieve an infection frequency of 1%-5% at the final dilution) was added and incubated at 37 C for 1 hour. 12.5 ml of cRMPI containing 4 3 10 6 Raji cells/ml was added to each well and incubated for another hour at 37 C. The cells were then pelleted, washed once with cRPMI, and re-suspended in cRMPI. Antibody concentration is reported relative to the final infection volume (50 ml). After 3 days at 37 C, cells were fixed in 2% paraformaldehyde. The percentage of GFP+ Raji cells as determined on a BD LSRII cytometer. To account for any false positive cells due to auto-fluorescence in the GFP channel, the %GFP+ cells in negative control wells (no virus, n = 5) was subtracted from each well. % neutralization in each well was defined as: [%GFP+ cells in the positive control wells containing virus alone (n = 5 wells) -%GFP+ cells in the antibody containing well] / %GFP+ cells in the positive control wells 3 100.
The % neutralization for each well was plotted as a function of the log 10 of the mAb concentration. The neutralization curve was fit using the log(inhibitor) versus response-variable slope (four parameters) analysis in Graphpad Prism 6 software.
Epithelial Cell Neutralization Assay 1.5 3 10 4 SVKCR2 cells per well were seeded into a 96 well tissue culture plate. The following day antibodies were serially diluted in duplicate wells containing 20 ml of media in a 96 well round bottom plate followed by the addition of 20 ml of 25 3 concentrated epithelial cell-tropic virus and incubated for 15 min. Media was aspirated from the SVKCR2 cells and replaced by the antibody-virus mixture followed by a 3 hour incubation at 37 C. The antibody-virus mixture was then aspirated and replaced with media. 48 hours later the cells were trypsinized and the percentage of GFP positive cells were determined on an BD LSRII cytometer. Percent neutralization was determined as in the B cell neutralization assay.
Cell Surface Binding Assays SA-PE conjugated to 0.5 mg of gH/gL biotin (gH/gL-PE), or to 0.5 mg of gB (gB-PE) was diluted in 10ml of PBS into individual wells of a 96 well plate. An equimolar amount of gp42 was added to select wells containing gH/gL-PE. 7 mg of monoclonal antibodies, AMMO1, AMMO4, or CL40 were added to select wells containing gH/gL ± gp42 and incubated for 1.5 hours at room temperature. Meanwhile, adherent AGS cells were trypsinized, washed with cF-12 and then allowed to recover at 37 C 5% CO 2 for 30 min. The cells were gently agitated and then returned to 37 C 5% CO 2 for an additional 30 min. Recovered AGS, and Raji cells were pelleted by centrifugation at 300 x g for 3 min and then resuspended at a density of 1 x10 6 cells/ml in ice-cold 0.5% bovine serum albumin (BSA) in PBS. 100 ml of AGS or Raji cells were added to wells containing SA-PE, SA-gB, SA-PE gH/gL ± gp42 and ± antibodies in quadruplicate, and incubated on ice for 1h. Cells were pelleted by centrifugation at 300 x g for 3 min, washed with 200 ml of ice cold 0.5% BSA in PBS, pelleted again and resuspended in 10% phosphate buffered formalin. The amount of PE staining was determined on a BD LSRII cytometer.
Virus Free Fusion Assay CHO-K1 cells were seeded onto six-well plates at a density of 3 3 10 5 cells/well. 24 hours later, the cells were transfected with 0.5 mg each of pCAGGS-gH, pCAGGS-gL, pCAGGS-gB (Haan et al., 2001 ) and 0.8 mg of pT7EMCLuc, which carries a luciferase-containing reporter plasmid under the control of the T7 promoter (Okuma et al., 1999) , using GeneJuice Transfection Reagent. Meanwhile, 293-T7 cells were seeded into a 96 well plate at a density of 1 3 10 4 cells per well in a volume of 100 ml/well of cF-12 without Zeocin selection.
8 hours later, the transfected CHO cells were trypsinized, washed once with cF-12, and re-suspended at a density of 1 3 10 5 cells/ml in F-12 media. 100 ml/well of CHO-K1 suspension was added to the plate containing 293-T7 cells. Immediately after the addition of CHO-K1 cells, 2 mg of AMMO1, AMMO3, AMMO5, or CL40 were added to 6 wells in parallel. 24 hours later, the media was aspirated and the cells were lysed in 100 ml of Steady-Glo luciferase reagent. 75 ml of cell lysate was transferred to a white bottom assay plate and luciferase activity was read on a Fluroskan Ascent FL fluorimeter.
Crystallization of the AMMO1 FAb and Data Collection
Crystals of AMMO1 Fab were obtained using a NT8 dispensing robot and screening was done with Rigaku Wizard Precipitant Synergy block#2, Molecular Dimensions Proplex HT-96, and Hampton Research Crystal Screen HT by the vapor diffusion method. Crystals used for diffraction data were grown in 16.75% PEG 400, 13.4% PEG 3350, 0.1M MgCl 2 , 0.1M Tris pH 8.5. Crystals were cryo-protected in solutions containing 30% molar excess of their original reagents and 20% Glycerol. Crystal diffracted to 1.6 Å (See Table S4 ). Data was collected at ALS 5.0.1 and 5.0.2 and processed using HKL2000 (Otwinowski and Minor, 1997) .
Structure Solution and Refinement
The structure of AMMO1 Fab was solved by molecular replacement using Phaser in CCP4 (Collaborative Computational Project, 1994) and PDB ID 4FQQ_L (light chain) and 4JPK_H (heavy chain) as search model. COOT(Emsley et al., 2010) and PHENIX (Adams et al., 2010 ) were used for model building and refinement of the structure, which included TLS parameters. A cross validation (Rfree) each gH/gL mutant, or mock transfected cells were pelleted by centrifugation at 300 x g for 3 min and then re-suspended in 200 ml of PBS containing 0.5% BSA and 2 mg of the CL59 mAb and incubated on ice for 1h. Meanwhile 3-fold serial dilutions of AMMO1 labeled with Dylite 650 were prepared in 50 ml of PBS containing 0.5% BSA in 96 well plates. 20 ml of PBS containing 0.5% BSA and 0.5 ml of PE-anti-mouse IgG was added to each well. Cells expressing gH/gL variants, as well as mock-transfected cells were washed with 3ml of PBS containing 0.5% BSA and resuspended in 650 ml of PBS containing 0.5% BSA. 30 ml of cell suspension was added to wells containing serially diluted AMMO1 and anti-mouse PE in duplicate, followed by a 1h incubation on ice. Each well was washed twice with 200 ml of PBS containing 0.5% BSA and then resuspended in 100 ml of 10% phosphate buffered formalin. gH/gL positive cells were determined by PE (CL59) staining, using mock-transfected cells as a reference. The level of AMMO1 binding to gH/gL was determined by measuring the mean fluorescence intensity (MFI) of DL650 staining of PE+ cells. To account for differences in gH/gL expression the MFI of PE staining for each gH/gL variant (16 wells total) was averaged and used to normalize the DL650 staining of each well. The normalized MFI of DL650 was plotted against the concentration of AMMO1 for each well and fit to a sigmoidal dose response curve using GraphPad Prism software.
Mass Spectrometry to Identify Glycopeptides
Approximately 250 pmol of gH/gL and gp42 were separately prepared for mass spectrometry analysis of glycopeptides. Stock solutions were denatured, reduced and alkylated by dilution to 5 mM in 50 mL of buffer containing 100 mM Tris pH 8.5, 10 mM TCEP, 40 mM iodoacetamide and 2% (w/v) sodium deoxycholate. Samples were first heated to 95 C for 10 min and then incubated for an additional 20-30 min at room temperature in the dark. The samples were split in two for digestion with trypsin and chymotrypsin in parallel, by diluting 20 mL of sample for each protease in a total volume of 100 mL 50 mM ammonium bicarbonate pH 8.5. Protease was added to the samples in a ratio of 1:75 by weight and left to incubate at 37 C overnight. After digestion, 2 mL of formic acid was added to the samples to precipitate the sodium deoxycholate from solution. After centrifugation for 20 min at maximum speed in a bench top centrifuge, 80 mL of the supernatant was collected. For each sample 8 mL was injected on a Thermo Scientific Orbitrap Fusion Tribrid mass spectrometer. A 35-cm analytical column and a 3-cm trap column filled with ReproSil-Pur C18AQ 5 mm beads (Dr. Maisch) were used. Nanospray LC-MS/MS was used to separate peptides over a 110-min gradient from 5% to 30% acetonitrile with 0.1% formic acid. A positive spray voltage of 2,100 V was used with an ion-transfer-tube temperature of 350
C. An electrontransfer/higher-energy collision dissociation ion-fragmentation scheme (Frese et al., 2013) was used with calibrated charge-dependent ETD parameters and supplemental higher-energy collision dissociation energy of 0.15. A resolution setting of 120,000 with an AGC target of 2 3 10 5 was used for MS1, and a resolution setting of 30,000 with an AGC target of 1 3 10 5 was used for MS2. Data was searched with Protein Metrics Byonic software (Bern et al., 2012) , using a small custom database of recombinant protein sequences including gH, gL, gp42, other viral glycoproteins and the proteases used to prepare the glycopeptides. Reverse decoy sequences were also included in the search. Specificity of the search was set to C-terminal cleavage at R/K (trypsin) or F/W/Y/M/L (chymotrypsin), allowing up to two missed cleavages, with EThcD fragmentation (b/y-and c/z-type ions). We used a precursor mass and product mass tolerance of 12 ppm and 24 ppm respectively. Carbamidomethylation of cysteines was set as fixed modification, methionine oxidation as variable modification, and all four software-provided N-linked glycan databases were used to identify glycopeptides. All glycopeptide hits were manually inspected and only those with quality peptide sequence information are reported here.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise noted, a two-tailed, unpaired t test was used to assess statistical significance. Statistical calculations were performed in Graphpad Prism. The number of replicates and a description of the statistical method are provided in the applicable figure legends. Data were considered statistically significant at * p < 0.05.
DATA AND SOFTWARE AVAILABILITY
Sequences for the VH/VL regions of the antibodies reported here can be found at GenBank under the accession numbers: KY631779-KY631788. Glycopeptide LC-MS/MS raw data and Byonic search results have been deposited in proteomics identification (PRIDE) database under PXD006403. The glycopeptides corresponding to gH, gL and gp42 can be found in Data S1 and S2. The cryoEM maps have been deposited in the Electron Microscopy Data Bank with accession code EMD-7344 (4.8Å ) and EMD-7345 (10 Å ). The atomic models of AMMO1 (PDB ID: 6BLA) and gH/gL-gp42-AMMO1 (PDB ID: 6C5V) have been deposited in the Protein Data Bank.
